Status:
COMPLETED
Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections
Lead Sponsor:
Pfizer
Conditions:
Complicated Urinary Tract Infection
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated urinary tract infections as compared to a comparator group.
Eligibility Criteria
Inclusion
- Acute pyelonephritis or other complicated urinary tract infection due to gram negative pathogens
Exclusion
- ileal loops or vesicoureteral reflux
- complete obstruction of any portion of urinary tract, perinephric or intrarenal abscess.
- fungal urinary tract infection
- permanent indirect catheter or nephrostomy unless removed within 48 hours of study entry
- history hypersensitivity to study medication
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
137 Patients enrolled
Trial Details
Trial ID
NCT00690378
Start Date
November 1 2008
End Date
July 1 2010
Last Update
May 25 2018
Active Locations (59)
Enter a location and click search to find clinical trials sorted by distance.
1
Alabama Research Center
Birmingham, Alabama, United States, 35209
2
Southeast Alabama Medical Center
Dothan, Alabama, United States, 36301
3
Providence Hospital
Mobile, Alabama, United States, 36608
4
Arizona Pulmonary Specialists LTD
Phoenix, Arizona, United States